As part of a long term strategy to meet increasing customer demands, CordenPharma has completed two additional key investments
to strengthen its development and manufacturing capabilities for Drug Product service offerings across its Highly Potent, Oncology
and Injectables Platforms
Firstly, CordenPharma is pleased to announce the completion and approval of its small-scale aseptic filling line
in CordenPharma Caponago
(IT). This addition to the existing terminal sterilization capabilities of the manufacturing facility will support customer development and commercial programs by providing expert service in aseptic-filling of liquid and lyophilized vials and pre-filled syringes for small molecules and peptides.
CordenPharma is additionally pleased to announce the completion and approval of expanded Development Capabilities (CTD2) for mid-scale (up to 20 kg) contained capacity of highly potent and oncology oral dosage forms
in its CordenPharma Plankstadt
(DE) manufacturing facility. This new and expanded capability provides customers a complete offering in the contained manufacturing of oral dosage from grams to 150 Kg.
, President of CordenPharma International
comments, “These new investments in oral and aseptic development capacities strengthen our ability to serve customers earlier in the pharmaceutical value chain. They are a clear indication of our overall commitment in responding to customers’ needs and are perfect complements to our existing API and Drug Product service offerings within our Highly Potent, Oncology and Injectables Platforms.
In addition, we anticipate further capacity expansion in the second half of 2016 by the completion of a second pharmaceutical oncology suite in CordenPharma Latina
(IT) to provide extended supply chain manufacturing services spanning development to commercial scale.”
These expansions enhance CordenPharma’s service offerings in the sterile and containment fields spanning from development to well-established worldwide commercial supply.
Read the full press release here.